跳至主要内容
临床试验/EUCTR2007-000054-31-GB
EUCTR2007-000054-31-GB进行中(未招募)1 期

An Open-Label, Phase IV, Multi-Centre Study to Investigate the Long-Term Safety and Efficacy of Subcutaneous Dynepo in Adult Patients with Anaemia Associated with Chronic Kidney Disease. - Dynepo long-term safety study

Shire0 个研究点目标入组 416 人开始时间: 2008年12月17日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
Shire
入组人数
416

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

入选标准

  • Patients who complete Dynepo study SPD490-301.
  • Patients who continue to require epoetin (EPO) treatment and have had a Hb level of >=10g/dL at Week 20 of study SPD490-301.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range

排除标准

  • Withdrawal, before Week 24, from SPD490-301.
  • Pregnant or lactating women.
  • Uncontrolled hypertension.
  • Thrombocytopenia (platelet count <75,000/mm3).
  • Active bleeding disorder (diathesis) (for example, gastrointestinal bleeding or genitourinary tract bleeding).
  • Treatment with immunosuppressive drugs (other than corticosteroids for a chronic condition) in the 30 days immediately prior to enrolment in this study.
  • Androgen therapy in the 30 days immediately prior to enrolment in this study.
  • Known Human Immunodeficiency Virus (HIV) infection.
  • History of hypersensitivity to Dynepo.
  • Known to have Ab against EPO.

研究者

发起方
Shire

相似试验

An Open-Label, Phase IV, Multi-Centre Study to... | 临床试验